A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

NCT03664232 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Autism Spectrum Disorder

Interventions

DRUG: JNJ-42165279
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC